medigraphic.com
Instituto Nacional de Salud Pública

2019, Number 3

<< Back

salud publica mex 2019; 61 (3)

Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system

Gerson R, Zatarain-Barrón ZL, Blanco C, Arrieta O

Language: English
References: 24
Page: 352-357
PDF size: 268.38 Kb.


ABSTRACT

Lung cancer is a major global public health problem, yet the disease is highly stigmatized, which impairs the opportunities to get optimal treatment for these patients. Globally, as well as locally in Mexico, lung cancer is the main cause of cancer-related deaths. Despite this, it is the only one among the five deadliest cancers in Mexico which is not covered by Popular Health Insurance. Lung cancer treatment is a complex algorithm, which requires fully trained personnel to assess each patient in order to determine standard-of-care therapy based on several factors associated with the molecular profile of the tumor, as well as patient characteristics and their financial capabilities. Coupled to this, in the recent decade, several breakthrough therapies have been launched, shifting the outlook for certain patient subgroups. However, none of these novel therapies are currently available to patients who have public-based health insurance. In this paper, we review the inequities present in the Mexican health system and highlight the importance of addressing these opportunities.


REFERENCES

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

  2. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. https://doi.org/10.1002/ijc.31937

  3. Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016;4(8):150. https://doi.org/10.21037/atm.2016.03.11

  4. Mohar-Betancourt A, Reynoso-Noveron N, Armas-Texta D, Gutierrez- Delgado C, Torres-Dominguez JA. Cancer trends in Mexico: Essential data for the creation and follow-up of public policies. J Glob Oncol. 2017;3(6):740-8. https://doi.org/10.1200/JGO.2016.007476

  5. Penman-Aguilar A, Talih M, Huang D, Moonesinghe R, Bouye K, Beckles G. Measurement of health disparities, health inequities, and social determinants of health to support the advancement of health equity. J Public Health Manag Pract. 2016;22(suppl 1):S33-42. https://doi.org/10.1097/ PHH.0000000000000373

  6. Farrer L, Marinetti C, Cavaco YK, Costongs C. Advocacy for health equity: a synthesis review. Milbank Q. 2015;93(2):392-437. https://doi. org/10.1111/1468-0009.12112

  7. World Health Organization. Health topics, Health equity, c2018 [cited 2019 March 1]. Available from: https://www.who.int/topics/health_equity/ en/

  8. Raez LE, Nogueira A, Santos ES, Dos Santos RS, Franceschini J, Ron DA, et al. Challenges in lung cancer screening in Latin America. J Glob Oncol. 2018(4):1-10. https://doi.org/10.1200/JGO.17.00040

  9. Arrieta O, Lopez-Mejia M, Macedo-Perez EO, Corona-Cruz JF. Proposals for the prevention of lung cancer in the health system of Mexico. Salud Publica Mex. 2016;58(2):274-8. https://doi.org/10.21149/spm. v58i2.7796

  10. Secretaría de Hacienda y Crédito Público. Paquete Económico para el Ejercicio Fiscal 2019, c2018 [cited 2019 March 1]. Available from: https://www.ppef.hacienda.gob.mx/

  11. Organization for Economic Cooperation and Development. OECD Reviews of Health Systems: Mexico 2016. Paris: OECD, 2016.

  12. Gómez-Dantés O, Sesma S, Becerril VM, Knaul FM, Arreola H, Frenk J. Sistema de salud de México. Salud Publica Mex. 2011;53(suppl 2):s220- 32. https://doi.org/10.1590/S0036-36342011000100016

  13. Comisión Interinstitucional del Cuadro Básico y Catálogo de Insumos del Sector Salud. Cuadro Básico y Catálogo de Medicamentos. Ciudad de México: Consejo de Salubridad General, 2016. Available from: http://www.csg.gob.mx/descargas/pdf/priorizacion/cuadro-basico/med/ catalogo/2016/EDICION_2016_MEDICAMENTOS.pdf

  14. Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan X, et al. New advances in immunotherapy for non-small cell lung cancer. Am J Transl Res. 2018;10(8):2234-45.

  15. Georgieva M, da Silveira-Nogueira-Lima JP, Aguiar P Jr, de Lima-Lopes G Jr, Haaland B. Cost-effectiveness of pembrolizumab as first-line thera py for advanced non-small cell lung cancer. Lung Cancer. 2018;124:248- 54. https://doi.org/10.1016/j.lungcan.2018.08.018

  16. Tamez-Gonzalez S, Eibenschutz C. El Seguro Popular de salud en México: pieza clave de la inequidad en salud. Rev Salud Publica. 2008;10(suppl 1):133-45. https://doi.org/10.1590/S0124- 00642008000600012

  17. Avila-Burgos L, Servan-Mori E, Wirtz VJ, Sosa-Rubi SG, Salinas- Rodriguez A. Efectos del Seguro Popular sobre el gasto en salud en hogares mexicanos a diez años de su implementación. Salud Publica Mex. 2013;55(suppl 2):S91-9. https://doi.org/10.21149/spm.v55s2.5103

  18. Comisión Nacional de Protección en Salud. Catálogo Universal de Servicios de Salud. Mexico City: Secretaría de Salud, 2018.

  19. Lu Y, Cheng J, Lin Z, Chen Y, Xuan J. Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China. J Med Econ. 2018;21(1):60-5. https://doi.org /10.1080/13696998.2017.1373654

  20. Baumgardner J, Shahabi A, Linthicum M, Vine S, Zacker C, Lakdawalla D. Greater spending associated with improved survival for some cancers in OCM-Defined episodes. J Manag Care Spec Pharm. 2018;24(6):504- 13. https://doi.org/10.18553/jmcp.2018.24.6.504

  21. QuintilesIMS Institute. Global Oncology Trends 2017. Advances, Complexity and Cost. Parsippany, NJ: QuintilesIMS Institute, 2017.

  22. Lu S, Ye M, Ding L, Tan F, Fu J, Wu B. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Oncotarget. 2017;8(6):9996-10006. https://doi.org/10.18632/oncotarget.14310

  23. Ting J, Tien-Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774-82. https://doi.org/10.1016/j.jval.2015.04.008

  24. Carlson JJ, Suh K, Orfanos P, Wong W. Cost Effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharmacoeconomics. 2018;36(4):495-504. https://doi.org/10.1007/s40273-018-0625-6




2020     |     www.medigraphic.com